The ability of ATN-224 to induce cell death in an isogenic cell model overexpressing Bcl-2 led to the hypothesis that ATN-224 treatment would be effective in DLBCL cells with upregulated Bcl-2. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.